Correlation of Nuclear Morphometry and Immunostaining for p53 and Proliferating Cell Nuclear Antigen in Transitional Cell Carcinoma of the Bladder

Background:

[1]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[2]  Osamu Yoshida,et al.  Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma , 1995, Cancer.

[3]  O. Yoshida,et al.  Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. , 1995, International journal of urology : official journal of the Japanese Urological Association.

[4]  S. Hsu,et al.  Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas. , 1995, Journal of biomedical science.

[5]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[6]  F. B. Sørensen,et al.  Qualitative and quantitative histopathology in transitional cell carcinomas of the urinary bladder. An international investigation of intra- and interobserver reproducibility. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[7]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[8]  O. Yoshida,et al.  Quantitative histopathology in the prognostic evaluation of patients with transitional cell carcinoma of the urinary bladder , 1993, Cancer.

[9]  F. Baluška,et al.  The role of the microtubular cytoskeleton in determining nuclear chromatin structure and passage of maize root cells through the cell cycle. , 1993, European journal of cell biology.

[10]  R. Takahashi,et al.  Accumulated allelic losses in the development of invasive urothelial cancer , 1993, International journal of cancer.

[11]  O. Yoshida,et al.  Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. , 1992, The Journal of urology.

[12]  P. Lipponen,et al.  Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. , 1992, British Journal of Cancer.

[13]  D. Schaid,et al.  Expression of p53 and 17p allelic loss in colorectal carcinoma. , 1992, Cancer research.

[14]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[15]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[16]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[17]  D. Lane,et al.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms , 1990, The Journal of pathology.

[18]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[19]  A. Partin,et al.  Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. , 1990, The Journal of urology.

[20]  L S Freedman,et al.  Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). , 1989, The Journal of urology.

[21]  J. Baak,et al.  The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. , 1989, American journal of clinical pathology.

[22]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[23]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[24]  A. Levine,et al.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells , 1984, Nature.

[25]  M. Boon,et al.  Analysis of the performance of pathologists in the grading of bladder tumors. , 1983, Human pathology.

[26]  J C Eggleston,et al.  A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. , 1982, The Journal of urology.

[27]  P. Esposti,et al.  The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours: a study of 100 untreated cases. , 1982, British journal of urology.

[28]  H. Busch.  The Cell Nucleus , 1966, Nature.

[29]  S. Hsu,et al.  Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. ii. from cytokines to cell lineage. , 1996, Journal of biomedical science.

[30]  P. Rathert,et al.  Cytologic Grading of Urothelial Tumors , 1993 .

[31]  F. B. Sørensen,et al.  Quantitative analysis of nuclear size for objective malignancy grading: a review with emphasis on new, unbiased stereologic methods. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[32]  P. Nichols,et al.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. , 1990, Cancer research.